- $489.43m
- $601.01m
- $297.18m
U.S. STOCKS ON THE MOVE-Viatris, National Fuel Gas, Moderna
Evolus rebounds after $50 mln stock offering
Brief: Evolus Announces Pricing Of $50.0 Million Underwritten Offering Of Common Stock
Evolus Inc reports results for the quarter ended in December - Earnings Summary
Brief: Evolus Reports Record Fourth Quarter And Full Year 2023 Financial Results Reaffirms 2024 Guidance
Brief: Evolus Q4 Net Income USD -11.831 Million
Brief: Evolus Announces Results From European Head-To-Head Filler Trial
U.S. STOCKS ON THE MOVE-Bullfrog AI, Sinclair, Humana
U.S. STOCKS ON THE MOVE-Snap, Charles Schwab, Tesla
Evolus rises on upbeat prelim Q4 revenue
Evolus rises on upbeat prelim Q4 revenue
AbbVie expects Botox market share to stay strong despite newer rivals (updated)
Brief: Evolus Enters Into Licensing Agreement With Symatese To Exclusively Distribute Next-Generation Dermal Fillers In Europe
US Consumer group seeks stronger warnings on Botox, similar treatments
Brief: Perceptive Advisors Llc Reports 5.4% Passive Stake In Evolus Inc
Brief: Evolus Q3 Net Income USD -16.923 Million
Brief: “Extra-Strength” 40U Formulation of Jeuveau Demonstrates Effects Lasting 26 Weeks in Phase II Data
Evolus Inc expected to post a loss of 17 cents a share - Earnings Preview
'Barbie Botox' goes viral but doctors inject caution (updated)